Osivax and GC Biopharma unveiled a major partnership to develop a more advanced influenza vaccine. The vaccine is set to combine OVX836 and GC FLU. Osivax obtained those rights for pursuing a combination shot.
Older adults must weigh four vaccine decisions this fall, while the federal schedule still lists a 2025 date. Flu and pneumonia deaths have dropped for 25 years, but one American age group posted an uptick.